Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Biomarin Pharmaceutical (BMRN) stock in plain English

Free brief · no signupStart here
BMRNPublished Nov 19, 2026
Biomarin Pharmaceutical Inc
Healthcare · Biotechnology
Develops and sells commercial biologics to treat rare genetic metabolic disorders and achondroplasia.
Assets:
Global Manufacturing HubOperates large-scale biologics production facility in Novato, California
Irish Production FacilityRuns drug substance manufacturing plant in Shanbally, Cork, Ireland
3,400 EmployeesEmploys scientists and commercial staff across North America, Europe, and Asia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

56
OPS ScoreOperating finances
Latest quote
-0.02%$61.42
$11.90B
n/a (loss)
$3.69B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BMRN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Biomarin Pharmaceutical (BMRN) do?

Biomarin Pharmaceutical Inc (BMRN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops and sells commercial biologics to treat rare genetic metabolic disorders and achondroplasia. Manufactures enzyme replacement and genetic therapies targeting rare diseases caused by specific metabolic gene. It is worth $11.90B on the market and sold $3.69B over the last year.

Market cap
$11.90B
P/E ratio
None (reported a loss)
Annual sales
$3.69B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind BMRN

  • Voxzogo: This daily injection increases linear growth in children with achondroplasia and generates revenue via global prescription sales.
  • Vimizim: This enzyme replacement therapy treats Morquio A syndrome and earns income from chronic hospital infusions.
  • Naglazyme: This enzyme replacement therapy treats MPS VI disease through recurring bi-weekly patient infusions.
  • Palynziq: This self-administered daily enzyme injection treats phenylketonuria in adults and earns money via pharmacy sales.
  • Roctavian: This one-time gene therapy treats severe hemophilia A and earns revenue through single-dose patient treatments.
  • Brineura: This enzyme infusion treats late infantile neuronal ceroid lipofuscinosis type 2 and earns revenue from specialized treatment centers.

BMRN’s flags, in plain English

Each flag is a number from Biomarin Pharmaceutical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Wide Gross Margin

Gross margin of 71.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Stupid Cash

Can pay this year's bills 2.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Burning Cash

Losing money, profit margin of -0.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag open with the free trial. Try it free for 7 days.

Questions about BMRN

How big is Biomarin Pharmaceutical?

Biomarin Pharmaceutical’s market cap is $11.90B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.69B: what customers paid the company over the last year, before any costs.

What is BMRN’s P/E ratio?

BMRN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with BMRN?

The business relies heavily on Voxzogo for ongoing sales expansion while competing pharmaceutical firms develop rival achondroplasia therapies. That is one risk on Biomarin Pharmaceutical’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Biomarin Pharmaceutical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BMRN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card